{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SARS-CoV-2+mRNA+Dose+2&page=2",
    "query": {
      "intervention": "SARS-CoV-2 mRNA Dose 2",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 67,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SARS-CoV-2+mRNA+Dose+2&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SARS-CoV-2+mRNA+Dose+2&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T10:33:14.584Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05004181",
      "title": "Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "SARS-CoV-2 Infection",
        "COVID-19",
        "SARS-CoV-2 Acute Respiratory Disease",
        "SARS (Disease)"
      ],
      "interventions": [
        {
          "name": "BNT162b2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Multivalent BNT162b2 (B.1.1.7 + B.1.617.2)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Monovalent BNT162b2 (B.1.1.7)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Monovalent BNT162b2 (B.1.617.2)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Monovalent BNT162b2 (B.1.1.529.1)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Observational",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "BioNTech SE",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 1380,
      "start_date": "2021-08-25",
      "completion_date": "2023-10-04",
      "has_results": true,
      "last_update_posted_date": "2024-11-22",
      "last_synced_at": "2026-10-23T10:33:14.584Z",
      "location_count": 14,
      "location_summary": "Long Beach, California • San Diego, California • Milford, Connecticut + 10 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Milford",
          "state": "Connecticut"
        },
        {
          "city": "Stamford",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05004181"
    },
    {
      "nct_id": "NCT04969276",
      "title": "Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza Immunization",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Quadrivalent Inactivated Influenza High Dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "COVID-19 mRNA Vaccine (nucleoside modified)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 306,
      "start_date": "2021-07-16",
      "completion_date": "2022-02-08",
      "has_results": true,
      "last_update_posted_date": "2025-09-12",
      "last_synced_at": "2026-10-23T10:33:14.584Z",
      "location_count": 6,
      "location_summary": "Glendale, Arizona • San Diego, California • Vista, California + 3 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Vista",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04969276"
    },
    {
      "nct_id": "NCT05975060",
      "title": "A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "XBB.1.5 Vaccine (Booster)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "XBB.1.5 Vaccine (single dose)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novavax",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "54 Years",
        "sex": "ALL",
        "summary": "18 Years to 54 Years"
      },
      "enrollment_count": 660,
      "start_date": "2023-09-07",
      "completion_date": "2024-05-20",
      "has_results": false,
      "last_update_posted_date": "2024-05-30",
      "last_synced_at": "2026-10-23T10:33:14.584Z",
      "location_count": 30,
      "location_summary": "Mobile, Alabama • Sacramento, California • Colorado Springs, Colorado + 26 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05975060"
    },
    {
      "nct_id": "NCT04796896",
      "title": "A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "SARS-CoV-2"
      ],
      "interventions": [
        {
          "name": "mRNA-1273",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1273.214",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "6 Months to 11 Years"
      },
      "enrollment_count": 11942,
      "start_date": "2021-03-15",
      "completion_date": "2024-03-15",
      "has_results": true,
      "last_update_posted_date": "2025-06-13",
      "last_synced_at": "2026-10-23T10:33:14.584Z",
      "location_count": 83,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 68 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Banning",
          "state": "California"
        },
        {
          "city": "El Monte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04796896"
    },
    {
      "nct_id": "NCT04761822",
      "title": "COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "SARS-CoV Infection",
        "COVID-19",
        "Allergic Reaction",
        "Mast Cell Disorder"
      ],
      "interventions": [
        {
          "name": "Moderna COVID-19 Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pfizer-BioNTech COVID-19 Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "5 Years and older"
      },
      "enrollment_count": 746,
      "start_date": "2021-04-07",
      "completion_date": "2022-04-27",
      "has_results": true,
      "last_update_posted_date": "2025-08-12",
      "last_synced_at": "2026-10-23T10:33:14.584Z",
      "location_count": 29,
      "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 24 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04761822"
    },
    {
      "nct_id": "NCT05925127",
      "title": "Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "NVX-CoV2373 (5μg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NVX-CoV2601(5μg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NVX-CoV2601(35μg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NVX-CoV2601(50μg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bivalent BA.4/5",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novavax",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "50 Years to 99 Years"
      },
      "enrollment_count": 994,
      "start_date": "2023-10-16",
      "completion_date": "2024-05-21",
      "has_results": false,
      "last_update_posted_date": "2024-12-13",
      "last_synced_at": "2026-10-23T10:33:14.584Z",
      "location_count": 50,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Banning, California + 44 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Banning",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05925127"
    },
    {
      "nct_id": "NCT04798027",
      "title": "Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "SARS-CoV-2 mRNA vaccine formulation 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 mRNA vaccine formulation 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 mRNA vaccine formulation 3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (0.9% normal saline)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 182,
      "start_date": "2021-03-12",
      "completion_date": "2022-06-27",
      "has_results": true,
      "last_update_posted_date": "2025-09-11",
      "last_synced_at": "2026-10-23T10:33:14.584Z",
      "location_count": 12,
      "location_summary": "Rolling Hills Estates, California • Hollywood, Florida • Miami, Florida + 9 more",
      "locations": [
        {
          "city": "Rolling Hills Estates",
          "state": "California"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04798027"
    },
    {
      "nct_id": "NCT04954287",
      "title": "Phase 1 Study of Intranasal PIV5 COVID-19 Vaccine Expressing SARS-CoV-2 Spike Protein in Healthy Adults and Adolescents",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "CVXGA1 low dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CVXGA1 high dose",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "CyanVac LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 72,
      "start_date": "2021-08-06",
      "completion_date": "2023-06-10",
      "has_results": false,
      "last_update_posted_date": "2024-02-07",
      "last_synced_at": "2026-10-23T10:33:14.584Z",
      "location_count": 4,
      "location_summary": "Bardstown, Kentucky • Rochester, New York • Cincinnati, Ohio + 1 more",
      "locations": [
        {
          "city": "Bardstown",
          "state": "Kentucky"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Plano",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04954287"
    },
    {
      "nct_id": "NCT05067933",
      "title": "A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "VXA-CoV2-1.1-S",
          "type": "DRUG"
        },
        {
          "name": "Placebo Tablets",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Vaxart",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 66,
      "start_date": "2021-10-22",
      "completion_date": "2023-05-09",
      "has_results": true,
      "last_update_posted_date": "2025-04-13",
      "last_synced_at": "2026-10-23T10:33:14.584Z",
      "location_count": 4,
      "location_summary": "Long Beach, California • Wichita, Kansas • Cleveland, Ohio + 1 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05067933"
    },
    {
      "nct_id": "NCT05028361",
      "title": "Simultaneous mRNA COVID-19 and IIV4 Vaccination Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Quality of Life",
        "Injection Site Reaction",
        "Adverse Drug Event",
        "Systemic Reaction"
      ],
      "interventions": [
        {
          "name": "mRNA COVID-19",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IIV4",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (saline)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "5 Years and older"
      },
      "enrollment_count": 348,
      "start_date": "2021-10-04",
      "completion_date": "2023-06-15",
      "has_results": true,
      "last_update_posted_date": "2024-03-19",
      "last_synced_at": "2026-10-23T10:33:14.584Z",
      "location_count": 3,
      "location_summary": "Baltimore, Maryland • Durham, North Carolina • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05028361"
    }
  ]
}